In a Perspective, Stephen Tang and Samuel Sternberg discuss retroelement-based gene editing as a safer alternative to CRISPR-Cas approaches.
Lexicon to face FDA AdComm for Zynquista approval in diabetes and CKD
In 2019, the FDA declined to approve Lexicon’s Zynquista as an adjunct to insulin in type 1 diabetes, citing safety concerns following a split 8-8